https://e-journal.unair.ac.id/JSCRTE Journal of Stem Cell Research and Tissue Engineering (JSCRTE) ( <a href="http://u.lipi.go.id/1512538326" target="_blank">p-ISSN: 2614-1264</a> ; <a href="http://u.lipi.go.id/1512447056" target="_blank">e-ISSN: 2614-1256</a> ) is published by Stem Cell Research and Development Center, Airlangga University. Stem Cell Research is dedicated to publishing high-quality manuscripts focusing on the biology and applications of stem cell research. Submissions to Stem Cell Research, may cover all aspects of stem cells, including embryonic stem cells, tissue-specific stem cells, cancerstem cells, developmental studies, genomics and translational research. Special focus of JSCRTE is on mechanisms of pluripotency and description of newly generated pluripotent stem cell lines. Articles that go through the selection process will be review by peer reviewer or editor. The journal is published regularly twice a year in December and May. Every publication consists of 60-70 pages and 5 scientific articles in the form of research, study literature, and the case study in English. The contributors Journal of Stem Cell Research and Tissue Engineering are Stem Cell researchers, lecturers, student and practitioners that came from Indonesia and abroad. Stem Cell Research and Development Center, Universitas Airlangga en-US Journal of Stem Cell Research and Tissue Engineering 2614-1264 <p><strong>1. As an author you (or your employer or institution) may do the following:</strong></p><ul><li>make copies (print or electronic) of the article for your own personal use, including for your own classroom teaching use;</li><li>make copies and distribute such copies (including through e-mail) of the article to research colleagues, for the personal use by such colleagues (but not commercially or systematically, e.g. via an e-mail list or list server);</li><li>present the article at a meeting or conference and to distribute copies of the article to the delegates attending such meeting;</li><li>for your employer, if the article is a ‘work for hire', made within the scope of your employment, your employer may use all or part of the information in the article for other intra-company use (e.g. training);</li><li>retain patent and trademark rights and rights to any process, procedure, or article of manufacture described in the article;</li><li>include the article in full or in part in a thesis or dissertation (provided that this is not to be published commercially);</li><li>use the article or any part thereof in a printed compilation of your works, such as collected writings or lecture notes (subsequent to publication of the article in the journal); and prepare other derivative works, to extend the article into book-length form, or to otherwise re-use portions or excerpts in other works, with full acknowledgement of its original publication in the journal;</li><li>may reproduce or authorize others to reproduce the article, material extracted from the article, or derivative works for the author's personal use or for company use, provided that the source and the copyright notice are indicated, the copies are not used in any way that implies JSCRTE endorsement of a product or service of any employer, and the copies themselves are not offered for sale.</li></ul><p>All copies, print or electronic, or other use of the paper or article must include the appropriate bibliographic citation for the article's publication in the journal.</p><p> </p><p><strong>2. Requests from third parties</strong></p><p>Although authors are permitted to re-use all or portions of the article in other works, this does not include granting third-party requests for reprinting, republishing, or other types of re-use. Requests for all uses not included above, including the authorization of third parties to reproduce or otherwise use all or part of the article (including figures and tables), should be referred to JSCRTE by going to our website at <a title="JSCRTE" href="/JSCRTE">http://e-journal.unair.ac.id/index.php/JSCRTE</a></p><p> </p><p><strong>3. Author Online Use</strong></p><ul><li>Personal Servers. Authors and/or their employers shall have the right to post the accepted version of articles pre-print version of the article, or revised personal version of the final text of the article (to reflect changes made in the peer review and editing process) on their own personal servers or the servers of their institutions or employers without permission from JSCRTE, provided that the posted version includes a prominently displayed JSCRTE copyright notice and, when published, a full citation to the original publication, including a link to the article abstract in the journal homepage. Authors shall not post the final, published versions of their papers;</li><li>Classroom or Internal Training Use. An author is expressly permitted to post any portion of the accepted version of his/her own articles on the author's personal web site or the servers of the author's institution or company in connection with the author's teaching, training, or work responsibilities, provided that the appropriate copyright, credit, and reuse notices appear prominently with the posted material. Examples of permitted uses are lecture materials, course packs, e-reserves, conference presentations, or in-house training courses;</li><li>Electronic Preprints. Before submitting an article to an JSCRTE, authors frequently post their manuscripts to their own web site, their employer's site, or to another server that invites constructive comment from colleagues. Upon submission of an article to JSCRTE, an author is required to transfer copyright in the article to JSCRTE, and the author must update any previously posted version of the article with a prominently displayed JSCRTE copyright notice. Upon publication of an article by the JSCRTE, the author must replace any previously posted electronic versions of the article with either (1) the full citation to the work with a Digital Object Identifier (DOI) or link to the article abstract in JSCRTE homepage, or (2) the accepted version only (not the final, published version), including the JSCRTE copyright notice and full citation, with a link to the final, published article in journal homepage.</li></ul><p> </p><p><strong>4. Articles in Press (AiP) service</strong></p><p>JSCRTE may choose to publish an abstract or portions of the paper before we publish it in the journal. Please contact our Production department immediately if you do not want us to make any such prior publication for any reason, including disclosure of a patentable invention.</p><p> </p><p><strong>5. Author/Employer Rights</strong></p><p>If you are employed and prepared the article on a subject within the scope of your employment, the copyright in the article belongs to your employer as a work-for-hire. In that case, JSCRTE assumes that when you sign this Form, you are authorized to do so by your employer and that your employer has consented to the transfer of copyright, to the representation and warranty of publication rights, and to all other terms and conditions of this Form. If such authorization and consent has not been given to you, an authorized representative of your employer should sign this Form as the Author.</p><p> </p><p><strong>6. JSCRTE Copyright Ownership</strong></p><p>It is the formal policy of JSCRTE to own the copyrights to all copyrightable material in its technical publications and to the individual contributions contained therein, in order to protect the interests of the JSCRTE, its authors and their employers, and, at the same time, to facilitate the appropriate re-use of this material by others. JSCRTE distributes its technical publications throughout the world and does so by various means such as hard copy, microfiche, microfilm, and electronic media. It also abstracts and may translate its publications, and articles contained therein, for inclusion in various compendiums, collective works, databases and similar publications</p><p> </p><p>Every accepted manuscript should be accompanied by "Copyright Transfer Agreement" prior to the article publication.</p><p> </p><p> </p> https://e-journal.unair.ac.id/JSCRTE/article/view/67764 <p>Recent advancements in stem cell biology, coupled with developments in space exploration, have opened new avenues for regenerative medicine. Microgravity environments in space induce significant physiological changes in the human body, such as muscle atrophy, decreased bone density, and immune system impairments, mimicking accelerated aging and chronic disease progression. These conditions offer a unique opportunity to study stem cell behavior, proliferation, and differentiation, which occur at a faster pace in space compared to Earth. The three-dimensional (3D) microgravity environment provides a more accurate representation of the human body’s natural state than traditional two-dimensional culture systems, fostering enhanced stem cell development. Among the various stem cells studied in space, mesenchymal stem cells (MSCs) have shown promise for therapeutic applications, including the treatment of stroke, cancer, and neurodegenerative diseases. Research aboard the International Space Station (ISS) has demonstrated that MSCs maintain their properties, proliferate, and differentiate under microgravity conditions, offering potential for future therapies. Additionally, MSCs exhibit resistance to space radiation, protecting astronauts from its harmful effects by promoting tissue repair and releasing regenerative factors. This radiation resistance, coupled with cryopreservation techniques, enables MSCs to be used in long-duration space missions. The ongoing research on MSCs in space not only supports astronaut health but also holds the potential to revolutionize regenerative medicine on Earth. By understanding how microgravity influences stem cell behavior, scientists are uncovering critical insights into tissue repair and cell function, paving the way for innovative treatments for aging-related diseases and other medical conditions. These findings highlight the broader implications of space-based stem cell research for advancing human health both in space and on Earth.</p> Hendrizal Copyright (c) 2024 Journal of Stem Cell Research and Tissue Engineering https://creativecommons.org/licenses/by/4.0/ 2024-12-28 2024-12-28 8 2 65 72 https://e-journal.unair.ac.id/JSCRTE/article/view/67760 <p>Cancer remains one of the leading causes of death worldwide, with various treatment options available depending on the type and stage of the disease. Traditional therapies, such as surgery, radiotherapy, chemotherapy, and immunotherapy, have shown varying degrees of success, but each has its limitations. Recently, stem cell therapies have emerged as a promising alternative, offering more targeted treatments with fewer side effects. Stem cells, including mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and cancer stem cells (CSCs), have demonstrated potential in cancer therapy through mechanisms like tumor site targeting, paracrine signaling, and gene delivery. MSCs, in particular, are of interest due to their ability to migrate to tumor sites and release exosomes that can influence tumor growth, angiogenesis, and metastasis. Modified MSCs have been engineered to deliver anticancer agents or "suicide" genes, providing a more focused approach to tumor treatment. Moreover, MSCs have shown promise in addressing challenges like drug resistance and recurrence in cancer. However, their effectiveness depends on factors such as exosome composition and the tumor microenvironment. Despite the challenges, stem cell-based therapies, including MSC-derived exosomes, represent a novel strategy to enhance the specificity and efficacy of cancer treatments. This review explores current advances in stem cell-based cancer therapies, highlighting their potential, ongoing research, and the need for further studies to optimize these approaches for clinical application.</p> Sumadi Copyright (c) 2024 Journal of Stem Cell Research and Tissue Engineering https://creativecommons.org/licenses/by/4.0/ 2024-12-28 2024-12-28 8 2 51 57 https://e-journal.unair.ac.id/JSCRTE/article/view/67765 <p>Stem cell research has paved the way for revolutionary regenerative therapies targeting damaged and diseased tissues. Beyond traditional cell transplantation, current evidence suggests that therapeutic benefits are primarily mediated through paracrine effects. Extracellular vesicles (EVs), which can traverse biological barriers and deliver bioactive molecules, represent a promising avenue for cell-free therapy. Tissue engineering, as the second-generation regenerative innovation, integrates biodegradable 3D scaffolds with cells to mimic natural extracellular matrices, enhancing therapeutic outcomes. This study examines the potential of EVs across diverse applications. In ocular regeneration, neural progenitor-derived EVs preserve photoreceptor cells and mitigate retinal inflammation in retinitis pigmentosa. For skin repair, EVs derived from mesenchymal stem cells (MSCs) support key phases of wound healing by modulating macrophage polarization and activating molecular pathways like RAC-alpha and Notch signaling. In cardiovascular therapy, EVs contribute to heart tissue recovery, reduce myocardial apoptosis, and combat fibrosis through targeted gene modulation. Skeletal muscle regeneration benefits from EVs enhancing myogenic differentiation, decreasing fibrosis, and addressing excessive extracellular matrix accumulation common in disorders like muscular dystrophy. The ability of EVs to emulate paracrine signaling processes expands the horizons of regenerative medicine, offering a scalable and efficient alternative to cell-based therapies. Literature highlights the critical role of high-quality, large-scale production under stringent standards to ensure therapeutic consistency. These findings underscore EVs as potent, cell-free agents capable of driving tissue repair and regeneration. Further investigations are encouraged to optimize production, application, and integration with advanced biomaterials for clinical efficacy.</p> Fitria Copyright (c) 2024 Journal of Stem Cell Research and Tissue Engineering https://creativecommons.org/licenses/by/4.0/ 2024-12-28 2024-12-28 8 2 73 80 https://e-journal.unair.ac.id/JSCRTE/article/view/67762 <p>Recent advancements in medical treatments, particularly gene therapy using hematopoietic stem cells (HSCs), have significantly impacted the treatment of inherited blood disorders. HSCs can self-renew and differentiate into blood cells, making them essential for treating conditions like sickle cell anemia, thalassemia, and severe combined immunodeficiency (SCID). This study conducted a literature review on autologous stem cell therapy for genetic blood disorders, analyzing studies from databases such as PubMed and Scopus. Gene therapy corrects genetic defects in HSCs, offering an alternative to allogeneic transplantation by avoiding immune rejection. The therapy involves modifying stem cells in the lab, often through viral vectors or gene-editing tools, and reinfusing them into the patient to produce healthy blood cells long-term. Lentiviral vectors, considered safer than retroviruses, have been particularly effective in treating various conditions, including immunodeficiencies and hemoglobinopathies. The ex vivo gene transfer approach, commonly used for genetic disorders, has shown promise for one-time curative treatments, especially for pediatric diseases. However, early gene therapy efforts, such as the use of gamma-retroviral vectors for SCID, faced complications like leukemia, leading to a shift towards safer lentiviral vectors. Despite its complexity, the procedure has a low failure rate and provides a less risky alternative to traditional allogeneic stem cell transplants. Ultimately, HSC gene therapy holds significant potential for curing genetic blood disorders by permanently altering the stem cells, ensuring long-term benefits and improved treatment outcomes, with ongoing advancements in safety and efficacy.</p> Nurul Faudhan Copyright (c) 2024 Journal of Stem Cell Research and Tissue Engineering https://creativecommons.org/licenses/by/4.0/ 2024-12-28 2024-12-28 8 2 58 64 https://e-journal.unair.ac.id/JSCRTE/article/view/67758 <p>The human body contains approximately 37.2 trillion cells, each specialized to perform specific functions within tissues and organs. Stem cells, particularly mesenchymal stem cells (MSCs), have emerged as a promising therapeutic option for various medical conditions due to their regenerative and differentiation capabilities. Female infertility, which significantly impacts quality of life, often results from reproductive disorders such as premature ovarian failure (POF), polycystic ovary syndrome (PCOS), endometriosis, Asherman syndrome, and preeclampsia. Conventional treatments like hormone therapy are limited by long-term risks, including heart disease and cancer, while assisted reproductive technologies are hindered by ethical, safety, and financial concerns. This review explores MSC-based therapies as innovative alternatives for addressing female reproductive disorders. MSCs demonstrate potential in regenerating ovarian cells, restoring hormonal balance, and repairing uterine tissue. For POF, MSC therapy replenishes ovarian cells, improves hormone levels, and restores function. In PCOS, MSCs reduce inflammation and fibrosis while enhancing ovarian function. Endometriosis management benefits from MSCs' ability to repair endometrial damage and improve uterine receptivity. MSCs also show efficacy in reducing fibrosis and increasing vascularization in Asherman syndrome and repairing placental damage in preeclampsia by mitigating oxidative stress and inflammation. This review synthesizes findings from recent studies to highlight MSCs' role in advancing gynecological medicine, presenting them as a safe, effective, and sustainable therapeutic approach for treating infertility and enhancing reproductive health.</p> Rizki Zeillatul Warda Copyright (c) 2024 Journal of Stem Cell Research and Tissue Engineering https://creativecommons.org/licenses/by/4.0/ 2024-12-28 2024-12-28 8 2 43 50